TOP SQUALENE SECRETS

AT 56Notwithstanding a variety of setbacks, various MDM2 inhibitors have now progressed into late-stage clinical advancement. New methods have also been developed to enhance the efficacy of MDM2 inhibitors and to mitigate their on-focus on toxicity. During this review, we summarize the progress and issues in the event of the MDM2 specific therapy.H